MX2012000275A - Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. - Google Patents
Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.Info
- Publication number
- MX2012000275A MX2012000275A MX2012000275A MX2012000275A MX2012000275A MX 2012000275 A MX2012000275 A MX 2012000275A MX 2012000275 A MX2012000275 A MX 2012000275A MX 2012000275 A MX2012000275 A MX 2012000275A MX 2012000275 A MX2012000275 A MX 2012000275A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- acid pump
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se refiere a un uso de un compuesto que tiene una actividad antagonista de bomba de ácido, una sal farmacéuticamente aceptable de éste o una composición farmacéutica de éste para la manufactura de un medicamento para la prevención o tratamiento de enfermedades en las cuales está involucrada motilidad gastrointestinal anormal. Además, la presente invención se relaciona con el método de prevención o tratamiento, el cual incluye la administración a un ser humano o animal. El compuesto, la sal farmacéuticamente aceptable de éste, o composiciones farmacéuticas que los contienen, pueden usarse en combinación con uno o más segundos agentes activos. Adicionalmente, la presente invención se refiere a composiciones farmacéuticas y kits que comprenden un compuesto que tiene actividad antagonista de bomba de ácido o una sal de éste farmacéuticamente aceptable para la prevención o tratamiento de dichas enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009163182 | 2009-07-09 | ||
JP2009188464 | 2009-08-17 | ||
PCT/JP2010/061660 WO2011004882A1 (ja) | 2009-07-09 | 2010-07-09 | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012000275A true MX2012000275A (es) | 2012-02-08 |
Family
ID=43429307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000275A MX2012000275A (es) | 2009-07-09 | 2010-07-09 | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. |
Country Status (12)
Country | Link |
---|---|
US (1) | US8648080B2 (es) |
EP (1) | EP2452680B1 (es) |
JP (4) | JP5802898B2 (es) |
KR (1) | KR101605063B1 (es) |
CN (2) | CN102470126A (es) |
BR (1) | BRPI1013288A2 (es) |
CA (1) | CA2765529C (es) |
ES (1) | ES2767251T3 (es) |
HK (1) | HK1225608A1 (es) |
MX (1) | MX2012000275A (es) |
RU (1) | RU2586276C2 (es) |
WO (1) | WO2011004882A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10709714B2 (en) | 2013-11-22 | 2020-07-14 | Clifton Life Sciences LLC | Gastrin antagonists for treatment and prevention of osteoporosis |
CN105708812A (zh) * | 2014-12-02 | 2016-06-29 | 江苏柯菲平医药股份有限公司 | 一种5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲氨冻干粉针及其制备方法 |
KR101684053B1 (ko) * | 2015-01-20 | 2016-12-08 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
MA41850A (fr) | 2015-03-31 | 2018-02-06 | Takeda Pharmaceuticals Co | Nouvelles utilisations pharmaceutiques |
DK3305291T3 (da) * | 2015-06-08 | 2021-06-28 | Hk Inno N Corp | Anvendelser af benzimidazolderivat mod natligt syregennembrud |
CN105078891B (zh) * | 2015-08-20 | 2018-04-24 | 寿光富康制药有限公司 | 一种tak-438脂质体及其制备方法和应用 |
CN105168131B (zh) * | 2015-09-17 | 2018-04-24 | 寿光富康制药有限公司 | 一种tak-438纳米乳的制备方法 |
CN106913859B (zh) * | 2015-12-25 | 2021-05-11 | 中美华世通生物医药科技(武汉)股份有限公司 | 药物组合物及制备方法 |
CN105663096B (zh) * | 2016-01-25 | 2019-06-14 | 南京济群医药科技股份有限公司 | 一种沃诺拉赞口腔速溶膜剂及其制备方法 |
KR101829706B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 산부가염 |
JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
CN112933091B (zh) * | 2020-09-07 | 2023-01-06 | 天地恒一制药股份有限公司 | 一种抗胃酸类疾病的药物组合物及应用 |
CN116507318A (zh) * | 2020-10-23 | 2023-07-28 | 怡诺安有限公司 | 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法 |
KR102648314B1 (ko) * | 2021-12-08 | 2024-03-15 | (주) 팜젠사이언스 | 벤즈이미다졸 유도체 화합물 및 이의 용도 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5996272A (ja) | 1982-11-26 | 1984-06-02 | Isuzu Motors Ltd | 金属表面の強化層形成方法 |
TW282460B (es) | 1993-12-28 | 1996-08-01 | Yamanouchi Pharma Co Ltd | |
CN1102144C (zh) * | 1994-08-13 | 2003-02-26 | 株式会社柳韩洋行 | 新的嘧啶衍生物及其制备方法 |
SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
SE9802793D0 (sv) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
SE9802794D0 (sv) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
IL142063A0 (en) * | 1998-09-23 | 2002-03-10 | Byk Gulden Lomberg Chem Fab | Tetrahydropyridoether derivatives and pharmaceutical compositions containing the same |
ATE386742T1 (de) | 1998-11-03 | 2008-03-15 | Nycomed Gmbh | Imidazonaphthyridine |
KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
TWI287014B (en) | 1999-06-15 | 2007-09-21 | Sankyo Co | Optically active pyrrolopyridazine compound |
AU783633B2 (en) | 2000-03-29 | 2005-11-17 | Altana Pharma Ag | Prodrugs of imidazopyridine derivatives |
AU2001294228A1 (en) | 2000-10-12 | 2002-04-22 | Takeda Chemical Industries Ltd. | Benzimidazole compounds, process for producing the same and use thereof |
EP1419163B9 (en) | 2001-08-10 | 2005-11-09 | ALTANA Pharma AG | Tricyclic imidazopyridines |
SE0102808D0 (sv) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
CA2506027A1 (en) | 2002-11-19 | 2004-06-03 | Altana Pharma Ag | 8-substituted imidazopyridines |
AR043063A1 (es) | 2002-12-13 | 2005-07-13 | Altana Pharma Ag | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas |
NZ542177A (en) | 2003-04-04 | 2009-02-28 | Altana Pharma Ag | Cyclic benzimidazoles for use against gastrointestinal disorders |
EP1644043A1 (en) * | 2003-05-27 | 2006-04-12 | ALTANA Pharma AG | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility |
SE0301905D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound I with therapeutic effect |
MXPA06002139A (es) | 2003-08-29 | 2006-05-31 | Dynogen Pharmaceuticals Inc | Composiciones utiles para tratar trastornos de la motilidad gastrointestinal. |
WO2005026164A1 (en) | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Pharmacologically active imidazo[4,5-c]pyridines |
AR046893A1 (es) | 2003-12-16 | 2005-12-28 | Altana Pharma Ag | Bencimidazoles triciclicos |
AR046941A1 (es) | 2003-12-19 | 2006-01-04 | Altana Pharma Ag | Imidazopiridinas triciclicas y su uso como inhibidores de secrecion de acido gastrico |
US20080033006A1 (en) | 2004-01-26 | 2008-02-07 | Altana Pharma Ag | 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors |
US20070167427A1 (en) | 2004-02-18 | 2007-07-19 | Altana Pharma Ag | 1,2,4-Triazolo[4,3-a]pyridines useful in the treatment of gastrointestinal disorders |
AU2005223389A1 (en) | 2004-03-17 | 2005-09-29 | Altana Pharma Ag | 7H-8,9-dihydro-pyrano (2,3-C) imidazo (1,2a) pyridine derivatives and their use as gastric acid secretion inhibitors |
AR048869A1 (es) | 2004-04-26 | 2006-06-07 | Altana Pharma Ag | Bencimidazoles triciclicos |
AU2005251943A1 (en) | 2004-06-09 | 2005-12-22 | Altana Pharma Ag | Substituted tricyclic benzimidazoles |
US7662832B2 (en) | 2004-09-03 | 2010-02-16 | Yuhan Corporation | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
AU2005280739B2 (en) | 2004-09-03 | 2010-11-11 | Yuhan Corporation | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof |
PL1784402T3 (pl) | 2004-09-03 | 2011-12-30 | Yuhan Corp | Pochodne pirolo[3,2-c]pirydyny oraz sposoby ich wytwarzania |
CA2582256A1 (en) | 2004-10-01 | 2006-04-13 | Altana Pharma Ag | Substituted tricyclic benzimidazoles |
AR051041A1 (es) | 2004-10-04 | 2006-12-13 | Altana Pharma Ag | Bencimidazoles triciclicos condensados |
AR051375A1 (es) | 2004-10-15 | 2007-01-10 | Altana Pharma Ag | Imidazopiridinas difluoro substituidas |
WO2006061380A2 (en) | 2004-12-09 | 2006-06-15 | Altana Pharma Ag | SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION |
KR101122376B1 (ko) | 2005-03-09 | 2012-03-26 | 주식회사유한양행 | 신규의 5,6-다이메틸피리미딘 유도체 및 그의 제조방법 |
KR101137168B1 (ko) | 2005-03-09 | 2012-04-19 | 주식회사유한양행 | 피롤로[2,3-d]피리다진 유도체 및 그의 제조방법 |
EP1910313A1 (en) | 2005-03-24 | 2008-04-16 | Nycomed GmbH | 6-thioamide substituted benzimidazoles |
US20080255358A1 (en) | 2005-03-24 | 2008-10-16 | Mark James Bamford | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases |
EP1863820A1 (en) | 2005-03-24 | 2007-12-12 | Nycomed GmbH | Thioamide-substituted tricyclic benzimidazoles useful for the treatment of gastrointestinal diseases |
AU2006243255A1 (en) | 2005-04-29 | 2006-11-09 | Nycomed Gmbh | Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity |
AR057061A1 (es) | 2005-06-16 | 2007-11-14 | Altana Pharma Ag | Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos |
JP2008546736A (ja) | 2005-06-22 | 2008-12-25 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式ベンゾイミダゾールの製造のための中間体の製造方法 |
GB0513423D0 (en) | 2005-06-30 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
JP2009504798A (ja) | 2005-08-22 | 2009-02-05 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 同位体置換されたベンゾイミダゾール誘導体 |
EP1919865B1 (en) * | 2005-08-30 | 2011-04-06 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
US7776873B2 (en) | 2005-12-01 | 2010-08-17 | Yuhan Corporation | Method for treating damage to gastric mucosa |
CN101341149B (zh) | 2005-12-19 | 2011-06-08 | 拉夸里亚创药株式会社 | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 |
EP2005957B1 (en) | 2006-03-31 | 2012-05-30 | Takeda Pharmaceutical Company Limited | Acid secretion inhibitor |
WO2008015196A1 (en) | 2006-07-31 | 2008-02-07 | Nycomed Gmbh | 5-,7-bis-substituted imidazo[1,2-a]pyridines |
MX2009000080A (es) * | 2006-09-21 | 2009-01-23 | Raqualia Pharma Inc | Derivados de bencimidazol como inhibidores selectivos de la bomba de acido. |
WO2008058990A1 (en) | 2006-11-16 | 2008-05-22 | Nycomed Gmbh | 7,7-disubstituted pyrano-[2,3-c]-imidazo-[1,2-a]-pyridine derivatives and their use as gastric acid secretion inhibitors |
WO2008071765A1 (en) | 2006-12-14 | 2008-06-19 | Nycomed Gmbh | Pharmaceutically active spiro-substituted benzimidazole derivatives |
WO2008071766A2 (en) | 2006-12-14 | 2008-06-19 | Nycomed Gmbh | Spiro-indene substituted imidazonaphythyridine and pyranoimidazopyridine derivatives as inhibitors of gastric acid secretion |
WO2008084067A2 (en) | 2007-01-12 | 2008-07-17 | Nycomed Gmbh | Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives |
WO2008095912A2 (en) | 2007-02-06 | 2008-08-14 | Nycomed Gmbh | Enantiopure pharmacologically active tricyclic benzimidazoles |
US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
WO2008151927A2 (en) | 2007-06-15 | 2008-12-18 | Nycomed Gmbh | 6-n-substituted benz imidazole derivatives as acid pump antagonists |
WO2009041447A1 (ja) | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
EP2190822B1 (en) | 2007-09-28 | 2014-12-31 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compounds as proton pump inhibitors |
-
2010
- 2010-07-09 KR KR1020127002781A patent/KR101605063B1/ko active IP Right Grant
- 2010-07-09 CN CN2010800308648A patent/CN102470126A/zh active Pending
- 2010-07-09 MX MX2012000275A patent/MX2012000275A/es active IP Right Grant
- 2010-07-09 CN CN201610246787.9A patent/CN105919998B/zh active Active
- 2010-07-09 ES ES10797193T patent/ES2767251T3/es active Active
- 2010-07-09 BR BRPI1013288A patent/BRPI1013288A2/pt not_active Application Discontinuation
- 2010-07-09 US US13/383,056 patent/US8648080B2/en active Active
- 2010-07-09 RU RU2012104533/15A patent/RU2586276C2/ru active
- 2010-07-09 CA CA2765529A patent/CA2765529C/en active Active
- 2010-07-09 WO PCT/JP2010/061660 patent/WO2011004882A1/ja active Application Filing
- 2010-07-09 EP EP10797193.9A patent/EP2452680B1/en active Active
- 2010-07-09 JP JP2011521969A patent/JP5802898B2/ja active Active
-
2013
- 2013-04-30 JP JP2013094888A patent/JP5699309B2/ja active Active
-
2014
- 2014-10-24 JP JP2014217434A patent/JP5978447B2/ja active Active
-
2016
- 2016-06-23 JP JP2016125015A patent/JP6212765B2/ja active Active
- 2016-12-05 HK HK16113855A patent/HK1225608A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN102470126A (zh) | 2012-05-23 |
CA2765529A1 (en) | 2011-01-13 |
JP2016166255A (ja) | 2016-09-15 |
KR20120052269A (ko) | 2012-05-23 |
US8648080B2 (en) | 2014-02-11 |
JP2015038140A (ja) | 2015-02-26 |
EP2452680A4 (en) | 2013-12-04 |
CA2765529C (en) | 2017-02-07 |
CN105919998B (zh) | 2021-08-24 |
EP2452680A1 (en) | 2012-05-16 |
EP2452680B1 (en) | 2019-12-18 |
HK1225608A1 (zh) | 2017-09-15 |
JP5802898B2 (ja) | 2015-11-04 |
RU2012104533A (ru) | 2013-08-20 |
CN105919998A (zh) | 2016-09-07 |
JP5978447B2 (ja) | 2016-08-24 |
ES2767251T3 (es) | 2020-06-17 |
RU2586276C2 (ru) | 2016-06-10 |
JP6212765B2 (ja) | 2017-10-18 |
KR101605063B1 (ko) | 2016-03-21 |
WO2011004882A1 (ja) | 2011-01-13 |
US20120115820A1 (en) | 2012-05-10 |
BRPI1013288A2 (pt) | 2016-03-29 |
JP5699309B2 (ja) | 2015-04-08 |
JP2013144719A (ja) | 2013-07-25 |
JPWO2011004882A1 (ja) | 2012-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
MX348705B (es) | Composiciones farmacéuticas y métodos de administración relacionados. | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
MX345032B (es) | Antagonistas del receptor ep4 para el tratamiento de cáncer. | |
MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
MX2009011900A (es) | Curacion de herida diabetica. | |
NZ599265A (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |